NCT03564340: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 1 year, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03564340 |
|---|---|
| Title | A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 21, 2018 |
| Completion date | June 21, 2026 |
| Required reporting date | June 21, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | July 4, 2025 |
| Days late | None |